Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | 1.00M | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.00M | 1.00M | 0.00 | 0.00 |
| Cost of Revenue | 90.38M | 77.04M | 68.03M | 68.34M | 71.84M |
| Gross Profit | -89.38M | -76.04M | -67.03M | -68.34M | -71.84M |
| SG&A Expenses | 71.16M | 65.48M | 43.38M | 47.38M | 56.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.54M | 142.52M | 111.41M | 115.72M | 127.90M |
| Operating Income | -160.54M | -141.52M | -110.41M | -115.72M | -127.90M |
| Income Before Tax | -153.16M | -133.29M | -102.56M | -108.29M | -121.30M |
| Income Tax Expenses | -- | -- | -1.13M | -1.12M | -1.10M |
| Earnings from Continuing Operations | -153.16 | -133.29 | -101.42 | -107.17 | -120.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.16M | -133.29M | -101.42M | -107.17M | -120.21M |
| EBIT | -160.54M | -141.52M | -110.41M | -115.72M | -127.90M |
| EBITDA | -157.20M | -137.87M | -106.56M | -111.25M | -122.85M |
| EPS Basic | -7.33 | -6.73 | -6.67 | -8.62 | -10.86 |
| Normalized Basic EPS | -4.58 | -4.21 | -4.24 | -5.46 | -6.86 |
| EPS Diluted | -7.33 | -6.73 | -6.67 | -8.62 | -10.86 |
| Normalized Diluted EPS | -4.58 | -4.21 | -4.24 | -5.46 | -6.86 |
| Average Basic Shares Outstanding | 83.56M | 79.11M | 68.33M | 57.55M | 46.78M |
| Average Diluted Shares Outstanding | 83.56M | 79.11M | 68.33M | 57.55M | 46.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |